Hsih-Te et al (Yang et al., 2022) have demonstrated that CD82 was a new synthetic lethality target for KRAS mutations and demonstrated digitonin as a potential therapeutic agent through a bioassay database of KRAS mutant colon cancer cell lines. Here, KRAS is linked to malignant colon neoplasm.